Washington Keeps Rescuing Telehealth Bupe at the Last Minute. That's Not a Policy.

Before the pandemic, Red was a chef in Portland who lost his job, then his apartment, then most of what he’d have called a plan. By early 2020 he was living in a homeless encampment, and by his own account he wasn’t even chasing a high anymore. “I wasn’t even getting high anymore,” he told Filter. “I was so sick of everything revolving around drugs.” What changed things wasn’t a bed opening at a clinic. It was a friend’s smartphone and a video call that ended, twenty minutes later, with a prescription for buprenorphine — the medication doctors call bupe or know by the brand name Suboxone, which eases opioid withdrawal and craving without the high of heroin or fentanyl. He never needed a ride or a waiting room. He needed a signal.

That video visit is legal today only because of a rule Washington keeps renewing instead of finishing. On December 31, 2025, the DEA and HHS issued a fourth temporary extension of the COVID-era rules letting a doctor prescribe buprenorphine by video, or by phone with no camera at all, without ever examining the patient in person. That door stays open only through December 31, 2026 — roughly 15 weeks from today.

Congress has spent six years treating a stopgap like a plan.

The Line They Keep Renewing Instead of Writing

The flexibilities at the center of this story were never supposed to last this long. They began in March 2020 as an emergency carve-out from the Ryan Haight Act, a 2008 law that had generally required a doctor to see a patient in person before prescribing anything on the DEA’s controlled-substances list — the federal classification system that flags medications, including buprenorphine, as having real medical value alongside real potential for misuse, and therefore extra rules about who can prescribe them and how. When the COVID-19 public health emergency ended in 2023, that in-person requirement was set to snap back into force, a moment inside the industry that got nicknamed the “telemedicine cliff.” DEA blinked. It issued a first temporary extension, then a second, then in January 2025 something that looked like a real answer: two final rules permanently allowing a single telehealth visit to justify up to six months of buprenorphine before a patient needs to be seen face to face. That permanent rule then got its own effective date pushed back twice, landing on December 31, 2025 — the same day the broader, looser flexibilities needed their fourth rescue.

Both things are true now: a narrow slice of buprenorphine telehealth is permanent law, and the much larger slice — audio-only inductions, ongoing prescribing with no prior in-person relationship at all, coverage for controlled medications beyond buprenorphine — is running on a rule DEA itself keeps calling temporary. The Federal Register notice says DEA and HHS need the extra year to “thoroughly consider” input from public listening sessions before writing anything final. It has now made a version of that same statement four times since 2023. The American Telemedicine Association’s advocacy arm has stopped being polite about the pattern. Alexis Apple, its deputy executive director, told Behavioral Health Business that this most recent decision “came within hours of expiration, placing patients, providers, and health systems on the brink of unnecessary disruption,” and that regulators need to “make all temporary telehealth waivers permanent or at least extended multiple years to avoid any lapses.” Her organization has been saying some version of that since 2023. So has nearly everyone else who treats people for opioid use disorder. Nobody with the authority to write a permanent rule has done it.

What Fifteen Weeks Feels Like From a Kitchen Table

If you’re the one who actually has to show up for the appointment, the fight in Washington probably looks smaller from where you’re standing than it is. Picture the ordinary version of this, not the abstract one: you’re two months into a job that doesn’t come with sick days, the nearest addiction medicine prescriber taking new patients is ninety minutes away, and the only reason you’ve stayed on buprenorphine instead of drifting back is that you can do the visit from your car during a lunch break, camera propped on the dashboard. That isn’t a scenario built by a think tank. It’s the ordinary shape of care that has taken hold since 2020, in exactly the population the system has always struggled hardest to reach — people without transportation, people in rural counties with no addiction specialist for a hundred miles, people who can’t take an afternoon off without losing the job that’s keeping them housed.

If you’re the one who actually has to show up for the appointment, the fight in Washington probably looks smaller from where you’re standing than it is.

It has also worked, by the numbers researchers have actually been able to collect. A 2026 multistate cohort study in the Journal of Medical Internet Research tracking tens of thousands of telehealth buprenorphine patients found 86.8 percent still in treatment after one month and 71.0 percent still retained at six months — figures researchers describe as comparable to, and in some analyses better than, historical rates for in-person-only care. A January 2026 Pew Charitable Trusts analysis points to the same pattern and to a harder number underneath it: of the estimated 5 million American adults living with opioid use disorder, only about one in five ever receives medication treatment at all — despite it being, according to Pew’s own review of the evidence, the single most effective option available. Telehealth didn’t fix that gap. It’s the biggest thing that’s narrowed it in a generation, especially for veterans, people experiencing homelessness, people involved in the criminal legal system, and people in rural communities who had functionally no other path to a prescriber.

None of that shows up as an abstraction to the person actually sitting in the video call. A young woman in upstate New York, revived by paramedics after an overdose and too scared to go to a hospital, connected with an addiction medicine prescriber from her own living room twenty minutes after the ambulance left and walked away with a buprenorphine prescription that same evening — a version of care described by Filter that simply did not exist as an option before 2020. Dr. Joshua Lynch, founder and medical director of the telehealth program NY MATTERS, told the outlet that a version of that story happens every day, and that the platform disproportionately reaches people who hadn’t received any addiction care anywhere before. Take the video option away, or leave it hanging on a year-to-year renewal that providers can’t build a program around, and that’s not a policy abstraction either. It’s a specific appointment that doesn’t happen.

The Model We Already Tried, and It Took Fifty Years to Loosen

None of this is the first time American drug policy has decided that access to a medication should run through a doctor’s ability to physically lay eyes on a patient. Methadone, the older of the two main medications for opioid use disorder, spent the better part of six decades locked into exactly that model, and the story of how it got there is the plainest evidence that today’s fight isn’t new — it’s a rerun with better internet. Concern about the drug being diverted, meaning sold or used by someone other than the patient it was prescribed for, drove the FDA to issue regulations in 1972 requiring that methadone for addiction treatment be dispensed only through federally licensed programs, with patients allowed to enroll in just one program and doses handed out under strict, often daily, in-person supervision. Congress then wrote that entire structure into law with the Narcotic Addict Treatment Act of 1974, permanently tying methadone to a network of dedicated clinics that, for decades afterward, faced fierce local opposition every time one tried to open in a new neighborhood — the same not-in-my-backyard fights that have kept treatment capacity thin in exactly the places that needed it most. That framework held almost unchanged until March 2020, when the same emergency that cracked open buprenorphine telehealth also let opioid treatment programs relax methadone’s take-home rules for the first time in generations, letting stable patients carry a week’s or a month’s supply home instead of drinking it under a nurse’s watch every single day.

The lesson from that half-century isn’t that regulators were wrong to worry about diversion. It’s that once a system built around scarcity and suspicion gets locked in — first in agency rule, then in statute — unlocking it again takes an emergency, not an argument. Buprenorphine’s telehealth access opened during a pandemic because pandemics are the rare kind of emergency that forces a bureaucracy to move fast. What nobody has yet supplied is the ordinary kind of political will it takes to make that opening permanent once the emergency has passed. This is a story that belongs as much to telehealth as it does to drug policy, because the mechanism doing the work here isn’t a new medication or a new clinical insight — it’s a video call, and whether the country is willing to trust one.

Buprenorphine’s telehealth access opened during a pandemic because pandemics are the rare kind of emergency that forces a bureaucracy to move fast.

Not everything on this particular clock is actually ticking. The rule DEA and HHS finalized in January 2025 — letting a single telehealth visit justify up to six months of buprenorphine before a patient needs an in-person exam — is permanent now, untouched by whatever happens this December. So is over-the-counter naloxone, the opioid overdose reversal medication sold without a prescription in pharmacies nationwide, with no telehealth visit and no renewal deadline attached to it at all. Those two facts don’t cancel out the other fifteen weeks. They’re proof the government knows exactly how to write something down permanently when it decides the fight is worth finishing — it just hasn’t decided that about the rest of this one yet.

Red doesn’t check the Federal Register. He found out telehealth buprenorphine existed because a friend handed him a phone at an encampment, and it worked well enough that he later moved into a city-sanctioned camp, got hired on staff there, and eventually transitioned to methadone maintenance — off the street, on a path he’d built one video visit at a time. What he told Filter about the calculus of staying on treatment rather than off it wasn’t complicated: a thirty-minute video conference and a script picked up at the pharmacy is a lot easier than chasing what comes next all day. Somebody in Washington keeps agreeing with him, one temporary year at a time. Nobody there has agreed to just say so for good.